Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement Gene
Overview
Authors
Affiliations
Background: Sequence analysis of the regulators of complement activation (RCA) cluster of genes at chromosome position 1q32 shows evidence of several large genomic duplications. These duplications have resulted in a high degree of sequence identity between the gene for factor H (CFH) and the genes for the five factor H-related proteins (CFHL1-5; aliases CFHR1-5). CFH mutations have been described in association with atypical haemolytic uraemic syndrome (aHUS). The majority of the mutations are missense changes that cluster in the C-terminal region and impair the ability of factor H to regulate surface-bound C3b. Some have arisen as a result of gene conversion between CFH and CFHL1. In this study we tested the hypothesis that nonallelic homologous recombination between low-copy repeats in the RCA cluster could result in the formation of a hybrid CFH/CFHL1 gene that predisposes to the development of aHUS.
Methods And Findings: In a family with many cases of aHUS that segregate with the RCA cluster we used cDNA analysis, gene sequencing, and Southern blotting to show that affected individuals carry a heterozygous CFH/CFHL1 hybrid gene in which exons 1-21 are derived from CFH and exons 22/23 from CFHL1. This hybrid encodes a protein product identical to a functionally significant CFH mutant (c.3572C>T, S1191L and c.3590T>C, V1197A) that has been previously described in association with aHUS.
Conclusions: CFH mutation screening is recommended in all aHUS patients prior to renal transplantation because of the high risk of disease recurrence post-transplant in those known to have a CFH mutation. Because of our finding it will be necessary to implement additional screening strategies that will detect a hybrid CFH/CFHL1 gene.
Tasaki Y, Tsujimoto H, Yokoyama T, Sugimoto N, Kitajima S, Fujii H Front Immunol. 2024; 15:1360855.
PMID: 38524137 PMC: 10957550. DOI: 10.3389/fimmu.2024.1360855.
The human factor H protein family - an update.
Sandor N, Schneider A, Matola A, Barbai V, Bencze D, Hammad H Front Immunol. 2024; 15:1135490.
PMID: 38410512 PMC: 10894998. DOI: 10.3389/fimmu.2024.1135490.
Lee H, Kim H, Lee H, Eum S, Sun I, Shin J Kidney Res Clin Pract. 2024; 43(1):125-129.
PMID: 38228318 PMC: 10846992. DOI: 10.23876/j.krcp.23.197.
Modeling complement activation on human glomerular microvascular endothelial cells.
Stevens K, Baas L, van der Velden T, Bouwmeester R, van Dillen N, Dorresteijn E Front Immunol. 2023; 14:1206409.
PMID: 37954621 PMC: 10634509. DOI: 10.3389/fimmu.2023.1206409.
Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome.
Connaughton D, Bhai P, Isenring P, Mahdi M, Sadikovic B, Schenkel L J Mol Med (Berl). 2023; 101(8):1029-1040.
PMID: 37466676 PMC: 10400659. DOI: 10.1007/s00109-023-02341-4.